FORM PTO-1390
(REV. 5-93)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER
2292/0H795

09/674462

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB99/01350	30 April 1999	30 April 1998

TITLE OF INVENTION

IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2(B7/CD28 INTERACTION)

APPLICANT(S) FOR DO/EO/US

Ian Robert LECHLER and Anthony DORLING

Applicant herewith submits to the United States Designated/Elected office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.

2. [] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S. C. 371.

3. [] This is an express request to begin national examination procedures (35 U.S.C. 371 (f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S. C. 371 (b) and PCT Articles 22 and 39 (1).

4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. [X] A copy of the International Application as filed (35 U.S. C. 371 (c) (2))
   a. [] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [X] has been transmitted by the International Bureau
   c. [] is not required, as the application was filed in the United States Receiving Office (RO/US)

6. [] A translation of the International Application into English (35 U.S. C. 371 (c)2)).

7. [] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [] have been transmitted by the International Bureau.
   c. [] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [] have not been made and will not be made.

8. [] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c) (3)).

9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned).

10. [] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. [] An Information Disclosure Statement under 37 CFR 1.97 and 1.98 (with ^C references).

12. [] An assignment document for recording. A **separate** cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

13. [X] A FIRST preliminary amendment.
    [] A SECOND or SUBSEQUENT preliminary amendment.

14. [] A substitute specification.

15. [] A change of power of attorney an/or address letter.

16. [] Other items or information:

EXPRESS MAIL CERTIFICATE
Date 10/30/00 Label No. EL 628223667US
I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, D.C. 20231 "Express Mail Post Office to Addressee" service.

D B Peck
Name (Print)

Signature

U.S. APPLICATION NO. (if known sec 37 C.F.R.1.50) 09/674462	INTERNATIONAL APPLICATION NO.: PCT/GB99/01350	Attorney's Docket Number 2292/0H795

17. [x] The following fees are submitted:	ALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492 (a)(1)-(5)): Search Report has been prepared by the EPO [X] or JPO []	**$860.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482)	**$690.00**	
No international preliminary examination fee paid to USPTO(37 CFR 4.482) but international search fee paid to USPTO (37 CFR 1.445 (a) (2)...	**$710.00**	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....	**$1,000.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....	**$100.00**	
ENTER APPROPRIATE BASIC FEE AMOUNT =		**$860.00**

Surcharge of $130.00 for furnishing the oath or declaration later than []20 []30 months from the earliest claimed priority date (37 CFR 1.492(e)).				$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	**30-20**	**10**	**10** X $18.00	**$180.00**	
Independent Claims	**6-3**	**3**	**3** X $80.00	**$240.00**	
Multiple dependent claims(s) (if applicable)		+270		$	
			TOTAL OF ABOVE CALCULATIONS =	**$1,280.00**	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				$	
			SUBTOTAL =	**$1,280.00**	
Processing fee of **$130.00** for furnishing the English translation later the [] 20 [] 39 months from the earliest claimed priority date (37 CFR 1.492(f)).			+	$	
			TOTAL NATIONAL FEE =	**$1,280.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). the assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property			+	$	
			TOTAL FEES ENCLOSED =	**$1,280.00**	
				Amount to be. refunded	$
				charged:	$

a. [X] A check in the amount of $1,280.00 to cover the above fees is enclosed.

b. [] Please charge my Deposit Account No.04-0100 in the amount of $ to cover the above fees.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-0100. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
Paul F. Fehlner
Darby & Darby P.C.
805 Third Avenue
New York, New York 10022-7513

SIGNATURE Paul F. Fehlner

NAME **Paul F. Fehlner**

REGISTRATION NO. **35,135**

EXPRESS MAIL CERTIFICATE

Date 10/30/00 Label No. EL628223667US

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D B Peek — D B Peek

Name (Print) Signature

2292/0H795

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ian Robert LECHLER and Anthony DORLING

Serial No: To Be Assigned
(U.S. National Phase of International Application No. PCT/GB99/01350 - filed 30 April 1999)

Filed: Concurrently herewith

For: IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2(B7/CD28 INTERACTION)

Honorable Commissioner of
Patents and Trademarks
BOX PCT
Washington, D.C. 20231
ATTN: DO/EO/US

PRELIMINARY AMENDMENT

Sir:

Prior to examination, applicants wish to amend the above-identified application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

10. (Amended) Nucleic acid which encodes a protein according to claim 8 [or claim 9].

11. (Amended) A cell which expresses a protein according to claim 8 [or claim 9] on its surface.

13. (Amended) An animal comprising a cell according to claim 11 [and/or biological tissue according to claim 12].

15. (Amended) A process for rendering biological tissue suitable for xenotransplantation, comprising the step of treating said biological tissue such that it expresses a protein according to claim 8 [or claim 9] on the surface of its cells.

16. (Amended) A protein according to claim 8 [or claim 9, or of nucleic acid according to claim 10,] in the preparation of a formulation for administration to a xenotransplant recipient or donor.

17. (Amended) The use of a protein according to claim 8 [or claim 9, or of nucleic acid according to claim 10,] in the preparation of a formulation for administration to a xenotransplant recipient or donor.

20. (Amended) A cell according to claim 18 [or claim 19], wherein said cell does not express B7 on its surface.

21. (Amended) A cell according to claim 18 (or claim 19], wherein said cell is a transected immature dendritic cell.

22. (Amended) Biological tissue comprising a cell according to [any one of claims 18, 19, 20 or 21] claim 18.

26. (Amended) A cell according to [any one of claims 18, 19, 20 or 21,] claim 18 for use as a medicament.

Please add claims 29 and 30:

-- 29. A biological tissue according to claim 12

30. A nucleic acid according to claim 10 in the preparation of a formulation for administration to a xenotransplant recipient or donor. --.

REMARKS

The claims have been amended to eliminate multiple claim dependencies.

Claims 29 and 30 have been added.

Entry of this amendment is respectfully requested.

Respectfully submitted,

Paul F. Fehlner
Registration No. 35,135
Attorney for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, N.Y. 10022
(212) 527-7700

IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2 (B7/CD28 INTERACTION)

This invention relates to the suppression of xenograft rejection.

BACKGROUND TO THE INVENTION

The success of allogeneic organ transplantation has been established in the last few decades, but the limited supply of donor organs means that many patients have little or no chance of receiving a transplanted organ, such as a kidney, heart or liver. A significant number of these people die whilst awaiting an organ. One potential solution is "xenografting", or the use of organs from a non-human ("xenogeneic") animal donor.

Porcine donor organs are thought to be suitable candidates because pigs are anatomically and physiologically similar to humans and are in abundant supply. Porcine organs are rejected rapidly upon revascularisation, however, by a humoral process called hyperacute rejection (HAR). This is caused by naturally-occurring antibodies in the recipient which recognise and cross-react with antigens on the endothelial cells (ECs) of the xenograft. This recognition triggers the complement cascade which in turn leads to rejection.

European patent 0495852 (Imutran) suggests that membrane-bound regulators of host complement should be expressed on the xenograft in order to prevent the complete activation of complement in the organ recipient. This approach has been developed and applied in order to produce transgenic animals with organs designed to survive hyperacute rejection [*eg.* refs 1 & 2].

However, organs surviving HAR are subject to delayed xenograft rejection (DXR). This is characterised by the infiltration of recipient inflammatory cells and thrombosis of graft vessels, leading to ischaemia. WO98/42850 shows that expression of coagulation inhibitors on the surface of the xenograft can inhibit the thrombotic aspect of this type of rejection.

HAR and DXR are followed by the host T lymphocyte-mediated response. There are two pathways, "direct" and "indirect" by which T-cells may become sensitised against xenoantigens. The direct pathway involves interactions between T-cells and MHC molecules on xenogeneic donor cells, whereas the indirect pathway involves the presentation of processed xenoantigens by host APCs in the context of MHC class II. The indirect T-cell response is much stronger against xenoantigens than against alloantigens [3], which contrasts with findings for the direct pathway [4], indicating that both the direct and indirect human T-cell responses against xenoantigens must be suppressed if xenotransplantation is to be effective.

It appears that the suppression of anti-xenograft indirect T-cell responses will be one of the greatest challenges for xenotransplantation [5,6]. Maintaining the level of immunosuppression required to prevent chronic xenograft rejection due to persistent indirect immunogenicity may be unfeasible using conventional systemic immunosuppressive drugs because of the increased the risks of infection and neoplasia [*eg.* 7]. Clearly, if xenotransplantation is to be clinically successful, methods to promote graft-specific immunosuppression are needed in order to reduce the requirements for systemic therapy.

T-cell activation requires two separate signals. Delivery of signal 1 alone induces a refractory state ("anergy"), defined as the inability to produce IL-2 after subsequent antigenic exposure. For full activation to occur, the cell must be co-stimulated with signal 2.

In vivo, signal 1 is provided by the interaction of the TCR/CD4 complex with either allogeneic MHC or antigenic peptide complexed with self MHC; signal 2 is supplied by the interaction between B7 molecules (B7.1 and B7.2, also known as CD80 and CD86, respectively) on the antigen-presenting cell (APC) and CD28 on the T-cell

Monoclonal antibodies (mAbs) have played a key role in studying T-cell activation. Signal 1 can be supplied by mAbs directed against the TCR/CD3 complex, and mAbs against CD28 can provide signal 2. Indeed, T-cells can be activated by two suitable mAbs, even in the absence of APC. Activation can also be prevented, rather than provided, using mAbs. Signal 2 can be blocked, for instance, using mAbs which block either B7 or CD28.

Signal 2 can also be blocked by using modified forms of CTLA-4, a high-affinity ligand for B7. CTLA-4 is a natural negative regulator of T-cell activation, and B7 binding to CTLA-4 on an activated T-cell antagonises the co-stimulatory signal provided by the B7/CD28 interaction. Soluble forms of CTLA-4, consisting of the extracellular domains of CTLA-4 linked to the constant domain of an antibody, have been constructed [8,9] to block T-cell activation. These molecules ("CTLA4-Ig" or "CTLA4-Fc") behave in a similar way to anti-B7 antibodies and have been used *in vitro* and *in vivo* to prevent the co-stimulatory functions of B7 and thus promote tolerance [10].

Targeting the B7/CD28 interaction to prevent T cell sensitisation to graft antigens *in vivo* has been shown to be an effective strategy to enhance graft survival. Using CTLA4-Ig, prolonged survival has been obtained in various allograft models [*eg.* 11] and in a human-to-murine islet xenograft model [12]. In the xenograft model, CTLA4-Ig administration caused full tolerance against the xenoantigens by rendering direct-reactive T cells anergic.

It is thus an object of the invention to provide means to promote xenograft-specific immunosuppression. In particular, it as an object of the invention to inhibit T-cell-mediated rejection of xenotransplanted organs by preventing the organ recipient's T-cells from mounting an immune response against the organ. More specifically, it is an object to prevent this immune response by inducing anergy in the recipient's T-cells which recognise the xenotransplanted organ, resulting in xenograft-specific T-cell tolerance.

DESCRIPTION OF THE INVENTION

The invention provides methods and biological reagents for inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 in order to prevent the activation of xenoreactive T-cells in the recipient.

This is embodied in three aspects, which are illustrated in Figure 1. It will be appreciated that these three aspects can be used in isolation or in various combinations. Furthermore, conventional immunosuppressive techniques may be used alongside those of the invention.

The following should be read in conjunction with the section entitled "Definitions", which begins on page 8.

The first aspect

In a first aspect, co-stimulation by signal 2 is prevented by administration to the organ recipient of a soluble form of CTLA-4 from the xenogeneic donor organism. If, for instance, a pig organ (donor) were being transplanted into a human (recipient), a soluble form of porcine CTLA-4 (see below) would be administered to the human.

Although CTLA-4 from one organism (*eg.* pig) is able to bind to B7 from another organism (*eg.* human), the highest avidity is found for allogeneic B7. Whilst soluble CTLA-4 from the donor organism can thus bind to both recipient B7 (on normal cells) and donor B7 (on xenotransplanted cells), it preferentially binds B7 on the xenograft. This results in xenograft-specific immunosuppression, unlike the administration of CTLA-4 from the recipient organism, which would tend to lead to systemic immunosuppression. By blocking the interaction between B7 on the xenogeneic donor cells and CD28 on recipient T-cells, co-stimulatory signal 2 is not delivered to the T-cell of the recipient. Xenoreactive recipient T-cells are therefore rendered anergic.

The invention thus provides a method of inducing xenotransplant tolerance in an organ recipient, comprising the administration to said recipient of a soluble form of the CTLA-4 protein from the xenogeneic donor organism.

The soluble form of CTLA-4 preferably comprises a fragment of the CTLA-4 from the donor organism which retains the ability to bind B7. This fragment is preferably the complete extracellular domain of CTLA-4.

Preferably, the soluble protein further comprises the constant domain of an immunoglobulin (*eg.* the Cγ1 chain of IgG1). Preferably, this is from the recipient organism, in order to prevent an immune response against this portion of the molecule.

In a typical embodiment for pig-to-human transplantation, therefore, the soluble protein could comprise the extracellular domain of porcine CTLA-4 fused to a human Cγ1 sequence.

Soluble forms of CTLA-4 from other organisms are described in, for instance, references 8 (human CTLA-4/human Ig γ1 constant region) and 9 (murine CTLA-4/human Ig γ1).

The invention also provides the use of a soluble form of xenogeneic CTLA-4 in the preparation of a medicament for inducing xenograft tolerance in an organ recipient.

The protein may be administered before, during, or after the xenotransplantation. Pre-xenotransplantation administration is most useful when the recipient is undergoing a pre-transplantation immunisation programme involving exposure to xenogeneic cells.

In the context of a pig being the donor organism, the invention provides a protein comprising the amino acid sequence shown in Figure 2 as SEQ ID:1, which is CTLA-4 cloned from porcine cells. This is the preferred form of CTLA-4 for use in the invention. The extracellular domain of this protein is also shown in Figure 2.

The invention also provides nucleic acid which encodes protein SEQ ID:1 (or fragments thereof). This preferably comprises the nucleotide sequence shown in Figure 3 as SEQ ID:2.

In addition, the invention provides a vector comprising the nucleic acid of the invention, and a cell transformed with such a vector.

The second aspect

In a second aspect, co-stimulation by signal 2 is antagonised by expressing a ligand for CTLA-4 on the xenogeneic donor cells. This ligand binds to CTLA-4 on activated T-cells of

the recipient and antagonises the co-stimulatory signal provided by the interaction between donor B7 and recipient CD28. This renders xenoreactive T-cells anergic.

The invention thus provides a membrane-associated protein which can bind to CTLA-4.

This will typically be a chimeric protein (*ie.* a protein produced by combining regions of different proteins into a single protein) comprising a CTLA-4-binding region and a membrane-association region. In its simplest form, the protein will thus be a fusion protein

By "membrane-associated protein", it is meant that the protein is attached to a cell membrane such that its extracellular domain can bind to CTLA-4. In order to attach the protein to the cell membrane, the protein might comprise a transmembrane sequence from a membrane protein, for instance, or a GPI anchor. A preferred transmembrane sequence is that of CD4 or CD8. Alternatively the protein might include a sequence which enables it to associate extracellularly with a membrane protein without the protein itself being inserted into the cell membrane.

It may also be desirable for the protein to comprise the cytoplasmic domain which is usually associated with said transmembrane regions (*eg.* the CD8 cytoplasmic domain), such that the protein is targeted to the cell membrane. Similarly, it may be desirable for the protein to comprise the extracellular sequences immediately juxtaposed with the cell membrane (*eg.* CD4 domains 3 and 4) in order to separate the CTLA-4-binding domain from the cell membrane. Synthetic linkers, such as glycine linkers, can be used for the same purpose.

The CTLA-4-binding domain of the protein preferably comprises an antibody with specificity for CTLA-4. This is preferably a single chain antibody (sFv). It is preferably specific for the CTLA-4 of a recipient organism.

In a typical embodiment, therefore, a protein of the second aspect can comprise a single chain antibody fused via a linker to the transmembrane and cytoplasmic domains of CD8.

The invention also provides nucleic acid which encodes a protein of the second aspect.

In addition, the invention provides a vector comprising said nucleic acid of the invention, and a cell transformed with said vector.

The invention also provides a delivery system comprising nucleic acid, and/or vector according to the second aspect of the invention, and means to deliver this material to a target cell.

Furthermore, the invention provides a cell which expresses a protein of the second aspect on its surface, preferably such that the protein can bind to available CTLA-4.

So that the cell can engage recipient T-cells, the cell preferably also expresses MHC (class I or class II) on its surface. Suitably, therefore, the cell of the invention is a donor professional APC. Because of the antagonistic signal provided by the anti-CTLA-4 protein, however, these professional APC behave functionally as B7-negative cells.

The invention also provides biological tissue comprising such a cell.

The invention further provides an animal comprising a cell and/or biological tissue according to the second aspect.

The invention also provides a process for rendering biological tissue suitable for xenotransplantation, comprising the step of treating said biological tissue such that it expresses one or more proteins according to the second aspect on the surface of its cells.

The invention also provides a method of transplantation comprising the step of transplanting biological tissue according to the invention from a donor animal (*eg.* a pig) into a xenogeneic recipient animal (*eg.* a human).

In addition, the cells of the invention are suitable for pre-transplantation administration. This results in tolerance being induced in recipient T-cells before the xenograft itself is transplanted. Whilst the cells used in such pre-transplantation regimes should preferably express MHC class II, it will be appreciated that the cells need not be professional APCs.

Furthermore, the invention provides protein or nucleic acid according to the second aspect for use as a medicament.

The invention also provides the use of protein, nucleic acid, a vector, or a delivery system according to the second aspect in the manufacture of a formulation for administration to a xenotransplant recipient or donor.

The third aspect

In a third aspect, co-stimulation by signal 2 is prevented by expressing recipient organism MHC class II on the surface of the cells of the xenogeneic donor organ. If, for instance, a pig organ (donor) were being transplanted into a human (recipient), the pig organ would express human MHC class II.

Even if direct activation of recipient T-cells is avoided, for instance by utilising one or both of the first two aspects of the invention described above, indirect activation can still occur, involving the processing and presentation of xenoantigens on MHC class II by recipient APC.

By expressing recipient MHC class II on the cells of the xenogeneic donor, the donor cells will present xenoantigens to a recipient T-cell in the context of self MHC class II. If the donor cells do not express B7, or if B7 is blocked, the xenoreactive recipient T-cell will not receive co-stimulatory signal 2 and will become anergic before the recipient's APCs have an opportunity to present the xenoantigens themselves.

The invention thus provides a cell which expresses on its surface MHC class II of a different organism. Preferably, this is a porcine cell expressing human MHC class II on its surface.

The MHC class II is preferably of the HLA-DR family.

The MHC class II is preferably constitutively expressed on the surface of the cells.

In order to prevent an allogeneic anti-MHC class II response, the MHC class II is preferably tissue-typed for maximum compatibility with the particular recipient. This will typically involve, for instance, ensuring that the HLA-DR expressed on the xenogeneic donor cell should match the HLA-DR of the particular recipient.

To ensure that xenoantigen display within the groove of the MHC class II molecule mirrors that found on professional APC, it is preferred that the cell should also express one or more of the following three proteins, each of which has an important role in antigen processing: invariant chain, HLA-DMα and HLA-DMβ.

The cell preferably does not express co-stimulatory molecules (*eg.* B7) on its surface. Typically, therefore, the donor cell is not a professional APC. It may, however, be a transfected non-immunogenic APC, such as an immature dendritic cell, which may be $B7^+$.

The invention also provides biological tissue comprising a cell according to the third aspect.

The invention further provides an animal comprising a cell and/or biological tissue according to the third aspect.

The invention also provides a process for rendering biological tissue suitable for xenotransplantation, comprising the step of treating said biological tissue such that it expresses xenogeneic MHC class II on the surface of its cells.

Preferably, this process comprises the steps of isolating non-immunogenic cells (*ie.* cells which cannot provide a co-stimulatory signal, such as B7-negative cells) from a xenogeneic organism and transfecting these cells with HLA-DR. The HLA-DR is preferably tissue-typed for a specific recipient. Furthermore, the cells may also be transfected with other proteins necessary for efficient antigen processing. Examples of suitable non-immunogenic cells include renal tubular

epithelial cells, which are B7-negative and have been shown to induce tolerance in rodent models of allogeneic transplantation.

The invention also provides a method of transplantation comprising the step of transplanting biological tissue according to the third aspect from a donor animal (*eg.* a pig) into a xenogeneic recipient animal (*eg.* a human).

In addition, the cells of the invention are suitable for pre-transplantation administration. This results in tolerance being induced in recipient T-cells before the xenograft itself is transplanted.

Furthermore, the invention provides a cell according to the third aspect for use as a medicament.

The invention also provides the use of a cell or of biological tissue according to the third aspect in the manufacture of a formulation for administering to a xenotransplant recipient.

The invention also provides the use of xenogeneic MHC class II, or nucleic acid encoding xenogeneic MHC class II, in the preparation of a formulation for administering to a xenotransplant donor.

Definitions

As used above, the term "nucleic acid" includes both DNA and RNA, although modified and synthetic nucleic acids are also included, For instance, the nucleic acid may be synthetic (*eg.* PNA), or may have modified inter-nucleotide linkages (*eg.* phosphorothioates). Furthermore, the term includes both sense and antisense nucleic acid sequences, as well as double-stranded sequences.

Preferably the nucleic acid comprises sequences suitable for the regulation of expression of protein according to the invention. This expression can preferably be controlled, such as cell-specific control, inducible control, or temporal control.

As used above, the term "vector" signifies a molecule which is capable of transferring nucleic acid to a host cell, and numerous suitable vectors are known in the art.

Preferably the vector is suitable for the production of a transgenic animal. Vectors suitable for the generation of transgenic pigs, for example, are described in references 13, 14, 15, 16 & 17.

As used above, the term "delivery system" refers to means for delivering genetic material to a target cell.

Certain vectors as described above may also function as suitable delivery systems. Likewise, certain delivery systems may also inherently be vectors, but this is not always the case. For instance, a viral vector can also function as a delivery system, whereas a liposomal delivery system is not a vector. The delivery system may be viral or non-viral. Non-viral systems, such as liposomes, avoid some of the difficulties associated with virus-based systems, such as the expense of scaled production, poor persistence of expression, and concerns about safety. Preferably the delivery system is suitable for use in gene therapy. Numerous appropriate delivery systems are known in the art.

Preferably, the delivery system will be targeted so that molecules according to the invention are taken up by cells suitable for xenotransplantation, or cells which have been transplanted. More preferably the delivery system will be specific for these cells. For example, the delivery system may be targeted to a specific organ, such as the heart or the kidney, or to a specific cell type, such as endothelial cells or professional APC.

To achieve this the delivery system may, for example, be a receptor-mediated delivery system, being targeted to receptors found on target cells. For example, the delivery system may be targeted to receptors found on heart cells, preferably to receptors found exclusively on heart cells, or it may be targeted to receptors found on endothelial cells, preferably to receptors found exclusively on endothelial cells.

The delivery system is preferably suitable for the generation of a transgenic animal. For example, the delivery system may be targeted to a gamete, a zygote, or an embryonic stem cell.

The vectors and delivery systems of the invention can be used to transfect cells to produce cells according to the invention. The transfection can occur *in vivo* or *ex vivo*.

The term "biological tissue" as used above includes collections of cells, tissues, and organs. Accordingly the definition includes, for example, fibroblasts, a cornea, nervous tissue, a heart, a liver, or a kidney.

Where the second and third aspects of the invention provide "an animal", said animal is preferably suitable for the production of organs for xenotransplantation and/or cells of the invention (*eg.* cells for pre-xenotransplant administration to xenograft recipients). Preferably the animal is a mammal, and more preferably it is a transgenic pig or a transgenic sheep.

The animal might be treated whilst alive such that it comprises transgenic biological tissue (*ie.* treated by gene therapy). Preferably, a live animal is transfected with a vector according to the

invention in order to produce a transgenic animal. For example, a vector according to the invention could be specifically delivered to the heart of a pig to produce biological tissue suitable for xenotransplantation.

Alternatively, the animal might be born as a transgenic animal. Many suitable approaches for generating such transgenic animals are known in the art [*eg.* refs. 18, 19, 20]. For example, direct manipulation of the zygote or early embryo, by microinjection of DNA for instance, is well known, as is the *in vitro* manipulation of pluripotent cells such as embryonic stem cells. Retroviral infection of early embryos has proved successful in a range of species, and adenoviral infection of zona-free eggs has been reported. Transgenesis and cloning of sheep by nuclear transfer has also been described (*eg.* WO97/07668).

Where the invention provides a process for rendering biological tissue suitable for xenotransplantation, said biological tissue may be so rendered either *in vivo* or *ex vivo*. For example, an animal organ may be *in vivo* transfected with a vector according to the invention, or an organ could be transfected *ex vivo* before transplantation or *in vivo* after transplantation.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described with reference to the attached drawings, in which:

Figure 1 illustrates the three aspects of the invention. "X" represents a xenogeneic cell (or, in the indirect activation pathway, a xenoantigen-presenting recipient APC), and "T" represents a recipient T-cell. In embodiment I, the delivery of co-stimulatory signal 2 is prevented by using a soluble form of CTLA-4. In embodiment II, anti-CTLA-4 is used to antagonise signal 2. In embodiment III, X expresses recipient MHC-II, but does not express B7.

Figure 2 shows the amino acid sequence of pCTLA-4 (SEQ ID NO:1). The following junctions are illustrated by a "*": signal peptide/extracellular domain; extracellular domain/transmembrane domain; transmembrane domain/cytoplasmic domain. An alignment with the human and bovine sequences is also shown. Homologies with pCTLA4 are:

Domain	Human	Bovine
Signal peptide	67.6%	86.5%
Extracellular domain	83.8%	84.6%
Transmembrane domain	96.1%	100%
Cytoplasmic domain	100%	100%
Overall	85.2%	89.2%

Figure 3 shows a similar alignment, but at the nucleotide level. Homologies are as follows:

Domain	Human	Bovine
Signal peptide	76%	81.3%
Extracellular domain	85.2%	86.3%
Transmembrane domain	92.3%	96.2%
Cytoplasmic domain	96.5%	97.7%
Overall	86.1%	88.3%

Figure 4 shows the amino acid sequence of the pCTLA4-Ig construct. The underlined sequence shows the flexible linker GGSGGAA, which also denotes the junction between pCTLA4 and the IgG1 domains.

Figure 5 shows the results of flow cytometric analysis of hCTLA4-Ig (○ & □) and pCTLA4-Ig (◊ & Δ) binding to human fibroblasts transfected with either human B7 (lower two lines) or porcine B7 (upper two lines).

Figure 6 shows the selective inhibition of proliferation by pCTLA4-Ig (○ & Δ) compared to hCTLA4-Ig (□ & ◊) when co-stimulated by human B7 (□ & ○) or porcine B7 (◊ & Δ).

Figure 7 shows the inhibition of human $CD4^+$ T cell proliferation by hCTLA4-Ig (□) or pCTLA4-Ig (◊) when human (7A) or porcine (7B) cells expressing MHC-class II were used as stimulators in a five day mixed leukocyte reaction.

Figure 8 shows the nucleotide sequence of an anti-human CTLA-4 sFv. The inferred protein sequence is shown in **Figure 9**. **Figure 10** shows the nucleotide sequences of four anti-murine CTLA-4 sFv. The inferred protein sequences are shown in **Figure 11**. The heavy and light chains are linked by a serine-glycine linker as indicated in Figures 9 and 11..

Figure 12 shows the construct encoding the soluble Ig-fusion of the CTLA-4-specific sFv.

Figure 13 shows the inhibition of T cell proliferation by cells expressing either an anti-hCTLA-4 sFv (□) or a control sFv (○).

Figure 14 shows construct encoding the membrane-bound form of the anti-CTLA-4 sFv.

Figure 15 shows (A) the nucleotide sequence and (B) the amino acid sequence of human CTLA-4. The start codon is underlined. At position –21, the sequence differs from GenBank sequence L15006, and at position 110 the sequence differs from both L15006 and M74363.

Figure 16 shows the sequence of cloned human CD8α. This differs from the GenBank sequence at positions 231 (T→G), 244 (A→G), 266 (T→C), and 437 (T→C).

Figure 17 shows the binding of human and murine CTLA4-Ig to IPEC, in order to define clones as B7-negative or B7-positive.

Figure 18 shows the binding to transfected cells of HLA-DR-specific mAb L243.

Figure 19 shows the proliferation by human T-cells to HLA-DR-1 transfected IPEC.

Figure 20 shows the results of a human T-cell proliferation assay following 2 days of incubation HLA-DR-1 transfected cells. The X-axis indicates the stimulator cells used in the second step of the proliferation assay. The black bars show results with CD4 T-cells which were primed with B7-positive transfectants; the white bars (hardly visible) show results after priming with B7-negative transfectants. The first graph shows results with cells harvested on day 3; the second graph shows results from a harvest on the sixth day.

Figure 21 shows the proliferation of an APC-dependent, HLA-DR-1 restricted T-cell line raised against IPEC. The stimulator population is indicated on the X-axis.

DESCRIPTION OF EMBODIMENTS

Soluble porcine CTLA-4

Porcine CTLA-4 ("pCTLA4") was cloned from PHA-activated pig T cells. RNA was prepared using standard techniques and pCTLA4 was amplified by PCR using primers:

5′-TTGAAGCTTAGCCATGGCTTGCTCTGGA-3′ (5' primer)

5′-TAATGAATTCTCAATTGATGGGAATAAAATAAG-3′ (3' primer)

The resulting 700bp fragment was sub-cloned into *EcoRI*/*Hind*III digested pBluescript, and the nucleotide sequence was determined using the standard T3 and T7 primers. The sequence of a single clone is shown in figure 3, which also shows a comparison with the human and bovine CTLA-4 sequences.

The predicted amino acid sequence of pCTLA4 is shown in figure 2, with a comparison with that of human and cattle. Of significance is the predicted amino acid difference at residue 97, which is important in B7 binding, being part of the conserved hexapeptide motif MYPPPY. In pCTLA4, residue 97 is leucine (giving LYPPPY), whereas other species have methionine (although leucine has also been found in bovine CD28 [21]). This important amino acid

difference is believed to be of key importance to the advantageous differential binding of pCTLA4 to human and pig B7.

The extracellular domain of pCTLA4 was amplified using the 5' primer described above and

5'-CGGTTCTGCAGCACCACCGGAGCCACCATCAGAATCTGGGCATGGTTCTGGATCAATGAC-3'

This amplified from position 484, introduced an 18 base-pair segment encoding a linker GGSGGAA sequence (underlined), and introduced a *Pst*I site (bold) to allow in-frame ligation to the hinge region of human IgG1. The resulting 500bp fragment was sub-cloned into *Hind*III/*Pst*I digested pBluescript-IgG1 containing genomic DNA encoding intronic sequences and the hinge, CH2, CH3 and 3' untranslated exons of human IgG1 between *Pst*I/*Not*I sites. The amino acid sequence of the resulting soluble pCTLA4-Ig is shown in figure 4.

Expression of pCTLA4-Ig

The chimeric pCTLA4-Ig DNA sequence was released from pBluescript as a *Hind*III/*Bst*XI fragment and was sub-cloned into the expression vector pHOOK-3™ (Invitrogen). This was used to transfect DAP.3 or CHO-K1 cells using standard calcium phosphate precipitation . G418-resistant cells were separated using the CaptureTec™ system. These transfected cells were grown in tissue culture flasks until confluent, at which point the medium was changed, and the cells were kept in culture for a further 3 days. At this stage the medium was harvested and perfused through a protein G column. pCTLA-4-Ig was eluted under acid conditions. The concentration of the eluted protein was calculated using ELISA with an antibody directed against human IgG1 and a standard human IgG1 myeloma protein.

The binding characteristics of pCTLA4-Ig were compared to those of human CTLA4-Ig using flow cytometric analysis with human fibroblasts transfected with either human B7-1 or porcine B7-2. For these experiments, the concentration of pig and human CTLA4-Ig were equivalent as assessed by ELISA. As illustrated in figure 5, human and porcine CTLA4-Ig appeared to have similar binding characteristics on human cells expressing porcine B7. Unlike human CTLA4-Ig, however, pCTLA4-Ig failed to bind human B7, implying that pCTLA4-Ig binds preferentially to porcine B7 and is useful as a species-specific reagent.

pCTLA4-Ig was used to inhibit human T cell proliferative responses to a variety of stimulators. In these assays, co-stimulation of the T cell response was provided by either porcine or human B7, expressed either by transfection or naturally on professional APCs. These experiments are demonstrated in figures 6 and 7.

In the experiments using transfected fibroblast stimulators (expressing HLA class II and either human or pig B7), hCTLA4-Ig inhibited all proliferative responses (Figure 6, □ & ◊). In contrast, pCTLA4-Ig only fully inhibited the response when stimulators expressed porcine B7 (Δ); the proliferative response to cells expressing human B7 was only minimally affected (○).

In similar experiments, pCTLA4-Ig failed to have a significant inhibitory effect on the proliferative responses to human cells expressing MHC class II and human B7 but did inhibit the response to porcine stimulators (figure 7).

These results highlight the effective inhibitory properties of pCTLA4-Ig when T cell co-stimulatory signals are provided by porcine B7. The failure to prevent T cell proliferation when co-stimulation is mediated by human B7 also demonstrates species-specific action. It can be concluded that pCTAL4-Ig shows species-specific binding to and inhibition of the functional effects of porcine B7, but not human B7.

Properties of pCTLA-4-Ig

The binding characteristics of pCTLA4-Ig to both human and porcine B7-family molecules may be compared to those of hCTLA4-Ig, for example using the following tests:

(i) flow cytometric analysis of binding to porcine and human APC, and to transfectants expressing porcine or human B7 (see above)

(ii) quantitative characterisation of binding using Biacore™.

(iii) functional analysis of the effects of CTLA4-Ig on human anti-pig and human allogeneic mixed lymphocyte cultures.

(iv) functional assessment of the ability of pCTLA4-Ig to prolong porcine islet xenograft survival after transplantation into B6 mice.

A membrane-associated protein which binds to CTLA-4

A phage display library containing 10^{12} semi-synthetic variable sequences was screened using human or murine CTLA4-Ig and a control human IgG1 myeloma protein. The sFv from a phage displaying differential binding to the human CTLA4-Ig protein after 4 rounds of screening were isolated and purified using standard techniques. The nucleotide and inferred amino acid sequences are shown in figures 8, 9, 10, and 11.

The sFv were amplified by PCR using specific primers based on the nucleotide sequences. The distal portions of the primers were based on sequence within pHOOK1. The 5' primer

contained an *ApaI* site and the 3' primer contained a *SalI* site, both of which were predicted to be unique. The resulting sFv were sub-cloned into pBluescript for sequencing to determine faithful amplification. The *ApaI/SalI* fragments were then sub-cloned into pHOOK1, where it is flanked upstream by an in-frame signal sequence from the murine Ig κ–chain and a haemagglutinin A epitope sequence, and downstream by two in-frame *myc* sequences and a transmembrane sequence from the PDGF receptor.

The *myc* sequences from pHOOK1 were amplified by PCR using the 5' primer 5'-GAGCTGAAACGGGCGGCCGCAGAAC-3', which contains a *NotI* site (underlined) and the 3' primer 5'-CTGGCCTGCAGCATTCAGATCC-3' , which introduced a *PstI* site (underlined). The resulting 113 base pair fragment was sub-cloned into *NotI/PstI* digested pBluescript.

The sFv was released from pHOOK1 as an *EcoRI/NotI* fragment, and was ligated into *EcoRI/PstI* digested pBluescript-IgG1, along with the *NotI/PstI* PCR product [Figure 12]. This construct encodes a soluble Ig-fusion of the CTLA-4-specific sFv. For expression in eukaryotic cells, the construct was sub-cloned into pHOOK3 as a *HindIII/BstXI* fragment.

To confirm cell-surface expression of the sFv, the pHOOK construct was transfected into cells already expressing HLA-DR molecules and human B7. Cells resistant to G418 or mycophenolic acid, depending on the vector used, were grown in culture. Cells expressing the anti-CTLA4-sFv construct on the cell surface were identified by flow cytometric analysis using hCTLA4-Ig. These cells were cloned by limiting dilution and were used as stimulators of T cell proliferation in 5 day cultures. The results of one experiment are shown in figure 13. Cells expressing the anti-hCTLA4 sFv failed to stimulate T cell proliferation (□), whereas those expressing a control sFv stimulated proliferation in the same way as normal cells (○).

In different experiments, the *EcoRI/SalI* fragment of the construct shown in Figure 12 was co-ligated with the transmembrane and cytoplasmic domains of human CD8 (isolated as a *SalI/BamHI* fragment from pBluescript-hCD8) into *EcoRI/BamHI* digested pBluescript [Figure 14].

The *EcoRI/BamHI* fragment from pBluescript was sub-cloned into the expression vector pHβApr-1-neo or the sister vector pHβApr-1-gpt. These were transfected into cells already expressing HLA-DR molecules and B7 and selected as described above for the pHOOK construct.

Membrane-associated CTLA-4 construct

The expression of CTLA-4 on by activated T-cells is only transient so, to test the functional characteristics of the anti-CTLA4-sFv, chimeric constructs comprising the DNA sequences encoding the extracellular domains of human or murine CTLA4 and the transmembrane/cytoplasmic sequences of human CD8 were made. Cells expressing these constructs can be used for the study of the anti-CTLA4-sFv protein.

RNA from PHA-activated human T cells was prepared using standard techniques. hCTLA4 was amplified PCR using primers:

5'-TTCAAAGCTTCAGGATCCTGAAAGGTTTTG-3' introducing a *Hind*III site (5' primer)

5'-TAATGAATTCTCAATTGATGGGAATAAAATAAG-3' introducing an *EcoR*I site (3' primer)

The resulting fragment was sub cloned into *Hind*III/*EcoR*I digested pBluescript and the nucleotide sequence determined using standard T3 and T7 primers. The sequence of a single clone is shown in figure 15. This differed by a single base (position 439) from GenBank-listed sequences for human CTLA-4. The predicted amino acid sequence of hCTLA4 is also shown.

The extracellular domain of hCTLA-4 was amplified using 5' primer described above and:

5'-GATGTAGATATCACAGGCGAAGTCGACACCACCGGAGCCACCAATTACATAAATCTGGGCTCCGTTGCCTATGCCC-3'

This amplified from position 457 and included a 15 base segment encoding a flexible GGSGG amino acid linker (underlined), along with a unique *Sal*I site (highlighted). The resulting fragment was sub cloned into *Hind*III/*Sal*I digested pBluescript and sequenced.

hCD8 was PCR-amplified from resting T-cells using primers:

5'-TCGCGCCCAAGCTTCGAGCCAAGCAGCGT-3' introducing a *Hind*III site (5' primer)

5'-TAATGAATTCTCAATTGATGGGAATAAAATAAG-3' introducing an *EcoR*I site (3' primer)

The resulting fragment was sub cloned into *Hind*III/*EcoR*I digested pBluescript and the nucleotide sequence determined using standard T3 and T7 primers. The sequence of a single clone is shown in figure 16. This clone differed from the sequence deposited with GenBank at four positions, although none of these were within the region that was subsequently amplified.

The transmembrane (TM) and cytoplasmic (C) domains of hCD8 were amplified using the 3' primer described above and the following 5' primer:

5'-CATAGGCAACGGAGCCCAGATTTATGTAATTGGTGGCTCCGGTGGTGTCGACTTCGCCTGTGATATCTACATC-3'

This amplified from position 532 and included a 15 base segment encoding a flexible GGSGG amino acid linker (underlined), along with a unique *SalI* site (highlighted). The resulting fragment was sub cloned into *Hind*III/*Sal*I digested pBluescript and called pBluescript-hCD8.

The extracellular domain of human CTLA-4 was cut from pBluescript as an *EcoR*I/*Sal*I fragment, and the TM-IC domain of CD8 cut as a *SalI*/*BamH*I fragment. Together they were ligated back into *EcoR*I/*BamH*I digested pBluescript. The whole CTLA-4-CD8 chimera was then removed as a single *EcoR*I fragment and was sub-cloned into a number of expression vectors for expression into the human T cell leukaemia line J6.

Properties of the cell-surface anti-CTLA4 proteins

The cell-surface anti-CTLA-4 proteins may be further characterised by the following functional tests:

i) Flow cytometric assessment of the interaction between cells expressing the membrane-bound anti-CTLA4-sFv-CD8 protein and soluble human CTLA4-Ig.

ii) Quantitative assessment of the interaction between the soluble anti-CTLA4-sFv-Ig fusion protein and soluble human CTLA4-Ig, using Biacore™

iii) Analysis on the signalling events resulting from the binding of soluble human CTLA4-Ig to J6 transfectants expressing the anti-CTLA4-sFv-CD8 fusion protein.

iv) Analysis of T cell responses (*eg.* proliferation, cytokine production, anergy induction) when stimulation in an allogeneic mixed lymphocyte response is provided by an HLA-DR-positive, B7-positive, anti-CTLA4-sFv-CD8-positive cell line.

B7-negative porcine cells expressing murine MHC class II

Fifty cloned immortalised porcine aortic endothelial cells (PAEC) were generated from monolayers of PAEC by intranuclear microinjection with pZipSVU19 DNA [22]. From the immortalised cells (IPEC), B7-negative clones were identified by flow cytometric screening with hCTLA4-Ig and mCTLA4-Ig [see figure 17]. These were then transfected with cDNAs encoding HLA-DRA and DRB1*0101 in the plasmid expression vectors pcExV1-gpt and pHβApr-1neo, and cells were placed under selection with MXH and G418. For comparison, B7-positive IPEC controls were generated similarly [4].

Another series of IPEC transfectants expressing the murine MHC class II molecule I-A^b were also generated for experiments in mice.

Surface expression of MHC class II on transfected IPEC cells was detected using monoclonal antibody L243 (specific for HLA-DR) [figure 18] or M5-114 (specific for murine MHC class II). MHC class II-positive cells underwent several rounds of fluorescence activated cell sorting before being cloned by limiting dilution.

A second batch of transfectants was prepared in exactly the same way, but with additional transfected cDNAs encoding HLA-DMA and HLA-DMB and p31Ii (invariant chain) in the expression vector pCMU.

Anergy induction in allogeneic T-cells by MHC class II-expressing cells

Human T-cells were purified using standard protocols [3]. For primary proliferation assays, T-cells were incubated for 5 days with fixed numbers of irradiated stimulator cells, before addition of 1μCi ^{3}H-thymidine sixteen hours prior to harvesting onto glass fibre filters. The filters were read in a scintillation counter.

B7-positive IPEC caused significant, anti-DR1 specific proliferative responses, whereas B7-negative IPEC failed to initiate any proliferative response [figure 19].

Two step anergy induction assays were established by a standard protocol [23]. In the primary, tolerance-induction step, T-cells incubated with B7-positive IPEC mounted an anti-DR1 proliferative response in the secondary step with the kinetics of a primed secondary immune response (maximal at three days). However, T-cells incubated with B7-negative IPEC in the primary step became tolerant to DR1 and failed to mount a response on subsequent exposure to DR1-expressed on B7-positive IPEC [figure 20].

Anergy induction in DR1-restricted T cells by DR1-expressing pig cells.

$CD4^{+}$ T-cells from a DR1-expressing individual were purified according to standard procedures. In primary proliferation assays, they proliferated to B7-positive IPEC transfected with HLA-DR1, indicating that the DR1 can perform as a restriction element for pig-peptide-specific T-cells. Assays comparing the proliferative response to B7-positive and B7-negative DR1+ transfectants are being performed.

Two step anergy induction assays may also be performed to demonstrate that DR1-transfected, B7-negative pig cells induce anergy in HLA-DR-restricted human T-cells.

Overlap between the pig peptides processed by professional human APC for presentation on HLA-DR and those presented on MHC class II of IPEC transfected with HLA-DR.

A human T-cell line against wild type IPEC was raised from human PBMC. The proliferative response of this line was dependent on the presence of human APC and inhibitable by antibodies against HLA-DR, indicating that the line had indirect specificity for processed porcine xenoantigens presented by human APC.

This line proliferated against B7-positive HLA-DR1-transfected IPEC [figure 21] implying that at least some of the processed pig peptides presented indirectly by professional human APC are also presented by transfected pig cells.

Studies in pig-islets-to-mouse model

In vivo, porcine pancreatic islet cells may be transplanted under the kidney capsule of streptozotocin-treated diabetic mice. Islet xenografts, being non vascular, are rejected solely by T-cells. Porcine islets are prepared from the pancreas of pigs under terminal anaesthesia, and their survival in the recipients assessed by maintenance of normoglycaemia. Mice are injected intravenously with B7-negative, I-A^b-expressing IPEC before transplantation of pig islets. This strategy can be combined with other aspects of the invention to tolerise the direct pathway of T-cell recognition, to ensure that rejection via the direct pathway does not occur. To assess whether a particular strategy has induced specific T-cell tolerance, nephrectomy of the islet-carrying kidney is performed before re-transplantation (under the capsule of the surviving kidney), of identical or third party porcine islets.

It will be understood that the invention is described above by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

REFERENCES (The contents of which are incorporated in full)

1 Squinto SP (1996) Xenogeneic organ transplantation. *Curr Opin Biotech* 7: 641-645.

2 McCurry *et al.* (1996) Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury. *Transplant Proc* 28: 758.

3 Dorling *et al.* (1996). Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. *Eur J Immunol* 26: 1378-1387.

4 Dorling *et al.* (1996) Cellular xenoresponses: Although vigorous, direct human T cell anti-pig primary xenoresponses are significantly weaker than equivalent alloresponses. *Xenotransplantation* 3: 149-157.

5 Auchincloss (1995) Why is cell-mediated xenograft rejection so strong? *Xeno* 3: 19.

6 Auchincloss (1988) Xenogeneic transplantation. *Transplantation* 46: 1.

7 Dorling *et al.* (1996) Cellular xenoresponses: Observation of significant primary indirect human T cell anti-pig xenoresponses using co-stimulator-deficient or SLA class II-negative porcine stimulators. *Xenotransplantation* 3: 112-119.

8 Linsley *et al.* (1991) CTLA-4 is a second receptor for the B-cell activation antigen B7. *J Exp Med* 174:561-569.

9 Lane *et al.* (1993) Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human γ1. *Immunology* 80: 56.

10 Cohen (1992) Mounting a targeted strike on unwanted immune responses. *Science* 257:751.

11 Baliga *et al.* (1994) CTLA4Ig prolongs allograft survival while suppressing cell mediated immunity. *Transplantation* 58: 1082-1090.

12 Lenschow *et al.* (1992) Long term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. *Science* 257: 789-792.

13 Heckl-Östreicher *et al.* (1995) Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human *in vtiro* model for hyperacture xenograft rejection. *Clin. Exp. Immunol.* 102:589-595.

14 McCurry *et al.* (1996) Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury. *Transplant Proc* 28: 758.

15 White *et al.* (1995) The control of hyperacute rejection by genetic engineering of the donor species. *Eye* 9: 185-189.

16 Yannoutsos *et al.* (1995) Production of pigs transgenic for human regulators of complement activation. *Transplant Proc* 27: 324-325.

17 Langford *et al.* (1996) Production of pigs transgenic for human regulators of complement activation using YAC technology. *Transplant Proc* 28: 862-863.

18 Bradley & Liu (1996) Target practice in transgenics. *Nature Genet* 14: 121-123.

19 Clarke (1996) The adenovirus and the egg: a new approach to transgenesis. *Nature Biotech.* 14:942.

20 Wheeler (1994) Development and validation of swine embryonic stem cells: a review. *Reprod Fertil Dev* 6:563-568.

21 Parsons *et al.* (1996) Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. *Immunogenetics* 43: 388-391.

22 Dorling *et al.* (1996) *In vitro* accommodation of immortalized porcine endothelial cells. *Transplantation* 62:1127-1136.

23 Marelli-Berg *et al.* (1996) Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. *J Exp Med* 183:1603.

CLAIMS

1. A biological reagent capable of inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 in order to prevent the activation of xenoreactive T-cells in the recipient.

2. A method for inhibiting T-cell mediated rejection of a xenotransplanted organ, comprising blocking the delivery of co-stimulatory signal 2 in order to prevent the activation of xenoreactive T-cells in the recipient.

3. A method according to claim 2, comprising the administration to said recipient to a soluble form of the CTLA-4 protein from the xenogeneic donor organism.

4. A method according to claim 3, wherein said soluble protein comprises the extracellular domain of porcine CTLA-4 fused to a human Cγ1 sequence.

5. A soluble form of xenogeneic CTLA-4 for use as a medicament.

6. A protein comprising the amino acid sequence SEQ ID:1

7. Nucleic acid which encodes the protein according to claim 6

8. A biological reagent according to claim 1, wherein said reagent is a membrane-associated protein which can bind to CTLA-4.

9. A protein according to claim 8, comprising a single chain antibody with specificity for CTLA-4.

10. Nucleic acid which encodes a protein according to claim 8 or claim 9.

11. A cell which expresses a protein according to claim 8 or claim 9 on its surface.

12. Biological tissue comprising a cell according to claim 11.

13. An animal comprising a cell according to claim 11 and/or biological tissue according to claim 12.

14. A method of transplantation comprising the step of transplanting biological tissue according to claim 12 from a donor animal into a xenogeneic recipient animal.

15. A process for rendering biological tissue suitable for xenotransplantation, comprising the step of treating said biological tissue such that it expresses a protein according to claim 8 or claim 9 on the surface of its cells.

16. A protein according to claim 8 or claim 9, or nucleic acid according to claim 10, for use as a medicament.

17. The use of a protein according to claim 8 or claim 9, or of nucleic acid according to claim 10, in the preparation of a formulation for administration to a xenotransplant recipient or donor.

18. A biological reagent according to claim 1, wherein said reagent is a cell which expresses on its surface MHC class II of a different organism.

19. A cell according to claim 18, wherein said cell is a porcine cell expressing human MHC class II on its surface.

20. A cell according to claim 18 or claim 19, wherein said cell does not express B7 on its surface.

21. A cell according to claim 18 or claim 19, wherein said cell is a transfected immature dendritic cell

22. Biological tissue comprising a cell according to any one of claims 18, 19, 20 or 21.

23. An animal comprising biological tissue according to claim 22.

24. A method of transplantation comprising the step of transplanting biological tissue according to claim 22 from a donor animal into a xenogeneic recipient animal.

25. A process for rendering biological tissue suitable for xenotransplantation, comprising the step of treating said biological tissue such that it expresses xenogeneic MHC class II on the surface of its cells.

26. A cell according to any one of claims 18, 19, 20 or 21, for use as a medicament.

27. The use of biological tissue according to claim 22 in the manufacture of a formulation for administering to a xenotransplant recipient.

28. The use of xenogeneic MHC class II, or nucleic acid encoding xenogeneic MHC class II, in the preparation of a formulation for administering to a xenotransplant donor.


T
X
APC
1
2
(I)
(II)
(III)
MHC + xenoantigen
TCR
CD28
B7
CTLA-4
Soluble CTLA-4
anti-CTLA-4

FIG. 1

FIG. 2

```
      -30         -20         -10           1           11          21
MACSGFRSHG AWLELTSRTW PCTALFSLLF IPVFSKGMHV AQPAVVLANS RGVASFVCEY
•••L••QR•K •Q•N•AA••• •••L••F••• ••••C•A••• ••••••••S• ••I•••••••
••••••Q••• T•W--••••• ••••••F•V• ••••••••N• T••P••••S• ••••••S•••
                                        *

       31          41          51          61          71          81
GSAGKAAEVR VTVLRRAGSQ MTEVCAATYT VEDELTFLDD STCTGTSTEN KVNLTIQGLR
A•P•••T••• •••••Q•D•• V•••••••••M MGN••••••• •I•••••SG• Q•••••••••
E•S•••D••• •••••E•••• V•••••G••M •••••••••• •••I•••RG• ••••••••••

       91         101         111         121         131         141
AVDTGLYICK VELLYPPPYY VGMGNGTQIY VIDPEPCPDS DFLLWILAAV SSGLFFYSFL
•M••••••••• •••MYPPPYY L•I•••A••• •••••••••• •••••••••• ••••••••••
•M•••••V•• •••MYPPPYY ••I••••••• •••••••••• •••••••••• ••••••••••
                                          *

       151         161         171         181
ITAVSLSKML KKRSPLTTGV YVKMPPTEPE CEKQFQPYFI PIN
L••••••••• •••••••••• •••••••••• •••••••••• •••
••••••••••  ••••••••••  ••••••••••  ••••••••••  •••
        *
```

SEQ ID:1 (pCTLA4)
Human CTLA4
Cattle CTLA4

09/674462

FIG. 3

```
361         371         381         391         401         411
GCCGTGGACA CTGGGCTCTA CATCTGCAAG GTGGAGCTCC TGTACCCACC ACCCTACTAT
•••A••••••  •G••A•••••  ••••••••••  •••••••••A  ••••••••••  G••A•••••C
•••A••••••  ••••••••••  TG•••••••A  •••••••••A  •••••••G••  G•••••••••C

421         431         441         451         461         471
GTGGGTATGG GCAACGGGAC CCAGATTTAT GTCATTGATC CAGAACCATG CCCAGATTCT
C••••C••A•  •••••••AG•  ••••••••••  ••A•••••••  •••••••G••  ••••••••••
•••••C••C•  ••••T••A••  •••••••••C  ••••••••••  ••••••••••  •••G••••••

481         491         501         511         521         531
GATTTCCTGC TCTGGATCCT GGCAGCAGTT AGTTCAGGGT TGTTTTTTTA CAGCTTCCTC
••C•••••C•  ••••••••••  T•••••••••  •••••G••••  ••••••••••  T•••••T•••
•••••T••C•  ••••••••••  ••••••••••  ••••••••••  •••••••C••  ••••••••••
   *
541         551         561         571         581         591
ATCACAGCTG TTTCTTTGAG CAAAATGCTA AAGAAAAGAA GTCCTCTTAC TACAGGGGTC
C•••••••••  ••••••••••  ••••••••••  ••••••••••  •C••••••••  A•••••••••
••••••••••  ••••••••••  ••••••••••  ••••••••••  •C••••••••  ••••••••••
                        *
601         611         621         631         641         651
TATGTGAAAA TGCCCCCGAC AGAGCCAGAA TGTGAAAAGC AATTTCAGCC TTATTTTATT
••••••••••  •••••••A••  ••••••••••  ••••••••••  ••••••••••  ••••••••••
••••••••••  •••••••A••  ••••••••••  ••••••••••  ••••••••••  ••••••••••

661         671
CCCATCAATT GA
••••••••••  ••
••••••••••  ••
```

SEQ ID: 2 (pCTLA4)
Human CTLA4
Cattle CTLA4

FIG. 3 (CONTD.)

09/674462
PCT/GB99/01350

FIG. 4

```
      -30         -20         -10           1           11          21
MACSGFRSHG AWLELTSRTW PCTALFSLLF IPVFSKGMHV AQPAVVLANS RGVASFVCEY

       31          41          51          61          71          81
GSAGKAAEVR VTVLRRAGSQ MTEVCAATYT VEDELTFLDD STCTGTSTEN KVNLTIQGLR

       91         101         111         121         131         141
AVDTGLYICK VELLYPPPYY VGMGNGTQIY VIDPEPCPDS DGGSGGAAEP KSCDKTHTCP

      151         161         171         181         191         201
PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA

      211         221         231         241         251         261
KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ

      271         281         291         301         311         321
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY

      331         341         351         361
SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
```

FIG. 5


1500
1000
500
0
Fluorescence
0.3125
0.625
1.25
2.5
5
10
20
40
Concentration of CTLA4-Ig (µg/ml)

FIG. 6


150
100
50
0
Proliferation (cpm x 10^{-3})
0
0.625
1.25
2.5
5
Concentration of CTLA4-Ig (µg/ml)

FIG. 7(A)


250
200
150
100
50
Mean CPM (x10-3)
0
0.625
1.25
2.5
5
Concentration of CTLA4-Ig (μg/ml)

FIG. 7(B)


60
40
20
0
Mean CPM (x10-3)
0
0.625
1.25
2.5
5
Concentration of CTLA4-Ig (μg/ml)

FIG. 8

```
1.........  11.........  21.........  31.........  41.........  51.........  61.........  71.........
CCGAGGTGCA  GCTGGTGGAG  TCTGGGGGAG  GCTTGGTACA  GCCTGGGGGG  TCCCTGAGAC  TCTCCTGTGC  AGCCTCTGGA

81.........  91.........  101.......  111.......  121.......  131.......  141.......  151.......
TTCACCTTTA  GCAGCTATGC  CATGAGCTGG  GTCCGCCAGG  CTCCAGGGAA  GGGGCTGGAG  TGGGTCTCAG  CTATTAGTGG

161.......  171.......  181.......  191.......  201.......  211.......  221.......  231.......
TAGTGGTGGT  AGCACATACT  ACGCAGACTC  CGTGAAGGGC  CGGTTCACCA  TCTCCAGAGA  CAATTCCAAG  AACACGCTGT

241.......  251.......  261.......  271.......  281.......  291.......  301.......  311.......
ATCTGCAAAT  GAACAGCCTG  AGAGCCGAGG  ACACGGCCGT  GTATTACTGT  GCAAGAGCTG  GTCGTATTTT  GTTTGACTAT

321.......  331.......  341.......  351.......  361.......  371.......  381.......  391.......
TGGGGCCAAG  GTACCCTGGT  CACCGTCTCG  AGTGGTGGAG  GCGGTTCAGG  CGGAGGTGGC  TCTGGCGGTA  GTGCACTTCA

401.......  411.......  421.......  431.......  441.......  451.......  461.......  471.......
GTCTGTGCTG  ACTCAGCCAC  CCTCAGCGTC  TGGGACCCCC  GGGCAGAGGG  TCACCATCTC  TTGTTCTGGA  AGCAGCTCCA

481.......  491.......  501.......  511.......  521.......  531.......  541.......  551.......
ACATCGGAAG  TAATTATGTA  TACTGGTACC  AGCAGCTCCC  AGGAACGGCC  CCCAAACTCC  TCATCTATAG  GAATAATCAG

561.......  571.......  581.......  591.......  601.......  611.......  621.......  631.......
CGGCCCTCAG  GGGTCCCTGA  CCGATTCTCT  GGCTCCAAGT  CTGGCACCTC  AGCCTCCCTG  GCCATCAGTG  GGCTCCGGTC

641.......  651.......  661.......  671.......  681.......  691.......  701.......  711.......
CGAGGATGAG  GCTGATTATT  ACTGTGCAGC  ATGGGATGAC  AGCCTGGTAT  TCGGCGGAGG  GACCAAGCTG  ACCGTCCTAG

721
GT
```

FIG. 9

```
1..... 11..... 21..... 31..... 41..... 51..... 61..... 71.....
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY

81..... 91..... 101..... 111..... 121..... 131..... 141..... 151.....
LQMNSLRAED TAVYYCARAG RILFDYWGQG TLVTVSSGGG GSGGGGSGGS ALQSVLTQPP SASGTPGQRV TISCSGSSSN
                                    LINKER

161..... 171..... 181..... 191..... 201..... 211..... 221..... 231.....
IGSNYVYWYQ QLPGTAPKLL IYRNNQRPSG VPDRFSGSKS GTSASLAISG LRSEDEADYY CAAWDDSLVF GGGTKLTVLG
```

FIG. 13



FIG. 10

```
                    10        20        30        40        50        60
                    |         |         |         |         |         |
M1 sFv      CATGG-CCGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAG
M3 sFv      CATGG-CCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTC
M19 sFv     CATGG-CCCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGGCCTCAGTGAA
M24 sFv     CATGGGCCCAGGTGCAGCTGTTGCAGTCTGCAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAA

                    70        80        90        100       110       120
                    |         |         |         |         |         |
M1 sFv      ACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGC--TA--TGCCAT--GAGCTGGGTCCGC
M3 sFv      CCTCACCTGCACTGTCTCTGGTGGCTCCGTCAGCAGTGGTAGTTACTACTGGAGCTGGATCCGG
M19 sFv     GGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGC------TACTATATGCACTGGGTGCGA
M24 sFv     GATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGC------TACTGGATCGGCTGGGTGCGC

                    130       140       150       160       170       180       190
                    |         |         |         |         |         |         |
M1 sFv      CAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT
M3 sFv      CAGCCCCCAGGGAAGGGACTGGAGTGGATT--GGGTAT-ATCTATTACAGTGGGAGCACCAACT
M19 sFv     CAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCT
M24 sFv     CAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGAT

                    200       210       220       230       240       250
                    |         |         |         |         |         |
M1 sFv      ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCT
M3 sFv      ACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCT
M19 sFv     ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACAT
M24 sFv     ACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCT

                    260       270       280       290       300       310       320
                    |         |         |         |         |         |         |
M1 sFv      GCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCAAGAGCTG------GT
M3 sFv      GAAGCTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCAAGAATGC------GG
M19 sFv     GGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCAAGAGTGGCTCCCTAT
M24 sFv     GCAGTGGAGCAGCCTGAAGGCCTCGGACACGGCCGTGTATTACTGTGCAAGATT--TTCGCT-T

                    330       340       350       360       370       380
                    |         |         |         |         |         |
M1 sFv      CGTATTTTGTTTGACTATTGGGGCCAAGGTACCCTGGTCACCGTCTCGAGTGGTGGAGGCGGTT
M3 sFv      AAGGATAAGTTTGACTATTGGGGCCAAGGTACCCTGGTCACCGTCTCGAGTGGTGGAGGCGGTT
M19 sFv     GTGAATACGCTTGTTTTTTGGGGCCAAGGTACCCTGGTCACCGTCTCGAGTGGTGGAGGCGGTT
M24 sFv     GGTGGT---TTTGACTATTGGGGCCAAGGTACCCTGGTCACCGTCTCGAGTGGTGGAGGCGGTT
```

```
                    390        400        410        420        430        440
                     |          |          |          |          |          |
M1 sFv      CAGGCGGAGGTGGCTCTGGCGGTAGTGCACTTCAGTCTGTGCTGACTCAG---CCACCCTCAGC
M3 sFv      CAGGCGGAGGTGGCTCTGGCGGTAGTGCACTTCAGTCTGTGCTGACTCAG---CCACCCTCAGC
M19 sFv     CAGGCGGAGGTGGCTCTGGCGGTAGTGCACTTTCTTCTGAGCTGACTCAG---GACCCTGCTGT
M24 sFv     CAGGCGGAGGTGGCTCTGGCGGTAGTGCACTTGACATCCAGTTGACCCAGTCTCCATCCTTCCT

                    450        460        470        480        490        500        510
                     |          |          |          |          |          |          |
M1 sFv      GTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAAGT
M3 sFv      GTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGAAGCAGCTCCAACATCGGAAGT
M19 sFv     GTCTGTGGCCTTGGGACAGACAGTCAGGATCACATGCCAAGGAGACAGCCTCA------GAAGC
M24 sFv     GTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCC---GGGCCAGTCAGGGCATT---AGC

                    520        530        540        550        560        570
                     |          |          |          |          |          |
M1 sFv      AATTATGTATACTGGTACCAGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTATAGGAATA
M3 sFv      AATTATGTATACTGGTACCAGCAGCTCCCAGGAACGGCCCCCAAACTCCTCATCTATAGGAATA
M19 sFv     TATTATGCAAGCTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTACTTGTCATCTATGGTAAAA
M24 sFv     AGTTATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTGGTCTATGCTGCAT

                    580        590        600        610        620        630        640
                     |          |          |          |          |          |          |
M1 sFv      ATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCT
M3 sFv      ATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCT
M19 sFv     ACAACCGGCCCTCAGGGATCCCAGACCGATTCTCTGGCTCCAGCTCAGGAAACACAGCTTCCTT
M24 sFv     CCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCT

                    650        660        670        680        690        700
                     |          |          |          |          |          |
M1 sFv      GGCCATCAGTGGGCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGC
M3 sFv      GGCCATCAGTGGGCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGC
M19 sFv     GACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTATTACTGTAACTCCCGGGACAGCAGT
M24 sFv     CACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCA---ACAGCTTAATAGT

                    710        720        730        740        750
                     |          |          |          |          |
M1 sFv      --CTG----GTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTGC
M3 sFv      --CTGT-TTGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTGCGGCCGC
M19 sFv     GGTTTTACTGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTGC
M24 sFv     TACCGCTTGACGTTCGGCCAAGGGACCAAGCTGGAAATC--AAACGTG----C
```

FIG. 10 *(CONTD.)*

FIG. 11


M1 sFv Peptide --EVQLVESGGGLVQPGGSLRLSCAASG--FTFSSYAMSWVRQAPGKGLEWVSAISGSGG
M3 sFv Peptide MAQVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSYYWSWIRQPPGKGLEWIGYIY-YSG
M19 sFv Peptide --QVQLVQSGAEVKRPGASVKVSCKASG--YTFTSYYMHWVRQAPGQGLEWMGIINPSGG
M24 sFv peptide --QVQLLQSAAEVKKPGESLKISCKGSG--YSFTSYWIGWVRQMPGKGLEWMGIIYPGDS
M1 sFv Peptide STYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAGR--ILFDYWGQGTLVT
M3 sFv Peptide SINYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMRK--DKFDYWGQGTLVT
M19 sFv Peptide STSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARVAPYVNTLVFWGQGTLVT
M24 sFv peptide DIRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAVYYCARFS--LGGFDYWGQGTLVT
M1 sFv Peptide VSSGGGGSGGGGSGGSALQSVLTQPPS-ASGTPGQRVTISCSGSSSNIGSNYVYWYQQLP
M3 sFv Peptide VSSGGGGSGGGGSGGSALQSVLTQPPS-ASGTPGQRVTISCSGSSSNIGSNYVYWYQQLP
M19 sFv Peptide VSSGGGGSGGGGSGGSALSSELTQDPA-VSVALGQTVRITCQGDS--LRSYYASWYQQKP
M24 sFv peptide VSSGGGGSGGGGSGGSALDIQLTQSPSFLSASVGDRVTITCRASQG--ISSYLAWYQQKP
M1 sFv Peptide GTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSL--VFG
M3 sFv Peptide GTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLF-VFG
M19 sFv Peptide GQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGFTVFG
M24 sFv peptide GKAPKLLVYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYRLT-FG
M1 sFv Peptide GGTKLTVLG
M3 sFv Peptide GGTKLTVLGAA
M19 sFv Peptide GGTKLTVLG
M24 sFv peptide QGTKLEI--KR

FIG. 12


EcoR1
Nco1
Apa1
Nco1
Not 1
Sal1
Pst1
Not 1
signal
HA
sFv
cMyc x 2
IgG1 constant domain

FIG. 14


EcoR1
Nco1
Apa1
Nco1
Not 1
Sal1
Not 1
signal
HA
sFv
cMycx1
hCD8 transmembrane/intracytoplasmic domains

FIG. 15(A)

```
-65  AGCTTCAGGA TCCTGAAAGG TTTTGCTCTA CTTCCTGAAG ACCTGAACAC
-15  CGCTCCCATA AAGCCATGGC TTGCCTTGGA TTTCAGCGGC ACAAGGCTCA
36   GCTGAACCTG GCTACCAGGA CCTGGCCCTG CACTCTCCTG TTTTTTCTTC
86   TCTTCATCCC TGTCTTCTGC AAAGCAATGC ACGTGGCCCA GCCTGCTGTG
136  GTACTGGCCA GCAGCCGAGG CATCGCCAGC TTTGTGTGTG AGTATGCATC
186  TCCAGGCAAA GCCACTGAGG TCCGGGTGAC AGTGCTTCGG CAGGCTGACA
236  GCCAGGTGAC TGAAGTCTGT GCGGCAACCT ACATGATGGG GAATGAGTTG
286  ACCTTCCTAG ATGATTCCAT CTGCACGGGC ACCTCCAGTG GAAATCAAGT
336  GAACCTCACT ATCCAAGGAC TGAGGGCCAT GGACACGGGA CTCTACATCT
386  GCAAGGTGGA GCTCATGTAC CCACCGCCAT ACTACCTGGG CATAGGCAAC
436  GGAACCCAGA TTTATGTAAT TGATCCAGAA CCGTGCCCAG ATTCTGACTT
486  CCTCCTCTGG ATCCTTGCAG CAGTTAGTTC GGGGTTGTTT TTTTATAGCT
536  TTCTCCTCAC AGCTGTTTCT TTGAGCAAAA TGCTAAAGAA AAGAAGCCCT
586  CTTACAACAG GGGTCTATGT GAAAATGCCC CCAACAGAGC CAGAATGTGA
636  AAAGCAATTT CAGCCTTATT TTATTCCCAT CAATTGAGAA TT
```

FIG. 15(B)

```
      -30        -20        -10         1          11         21
MACLGFQRHK AQLNLATRTW PCTLLFFLLF IPVFCKAMHV AQPAVVLASS RGIASFVCEY
                                          *

      31         41         51         61         71         81
ASPGKATEVR VTVLRQADSQ VTEVCAATYM MGNELTFLDD SICTGTSSGN QVNLTIQGLR

      91         101        111        121        131        141
AMDTGLYICK VELMYPPPYY LGIGNGTQIY VIDPEPCPDS DFLLWILAAV SSGLFFYSFL
                                           *

      151        161        171        181
LTAVSLSKML KKRSPLTTGV YVKMPPTEPE CEKQFQPYFI PIN
       *
```

FIG. 16

-36 AAGCTTCGAG CCAAGCAGCG TCCTGGGGAG CGCGTCATGG CCTTACCAGT

15 GACCGCCTTG CTCCTGCCGC TGGCCTTGCT GCTCCACGCC GCCAGGCCGA

65 GCCAGTTCCG GGTGTCGCCG CTGGATCGGA CCTGGAACCT GGGCGAGACA

115 GTGGAGCTGA AGTGCCAGGT GCTGCTGTCC AACCCGACGT CGGGCTGCTC

165 GTGGCTCTTC CAGCCGCGCG GCGCCGCCGC CAGTCCCACC TTCCTCCTAT

215 ACCTCTCCCA AAACAATCCC AAGGCGGCCA AGGGGCTGGA CACCCAGCGG

265 TTCTCGGGCA AGAGGTTGGG GGACACCTTC GTCCTCACCC TGAGCGACTT

315 CCGCCGAGAG AACGAGGGCT ACTATTTCTG CTCGGCCCTG AGCAACTCCA

365 TCATGTACTT CAGCCACTTC GTGCCGGTCT TCCTGCCAGC GAAGCCCACC

415 ACGACGCCAG CGCCGCGACC ACTAACACCG GCGCCCACCA TCGCGTCGCA

465 GCCCCTGTCC CTGCGCCCAG AGGCGTGCCG GCCAGCGGCG GGGGGCGCAG

515 TGCACACGAG GGGGCTGGAC TTCGCCTGTG ATATCTACAT CTGGGCGCCC

565 CTGGCCGGGA CTTGTGGGGT CCTTCTCCTG TCACTGGTTA TCACCCTTTA

615 CTGCAACCAC AGGAACCGAA GACGTGTTTG CAAATGTCCC CGGCCTGTGG

665 TCAAATCGGG AGACAAGCCC AGCCTTTCGG CGAGATACGT CTAACCCTGT

715 GCAACAGCCA CTACATGAAT TCC

FIG. 17


B7+ IPEC
hCTLA4-Ig
mCTLA4-Ig
B7 – IPEC
hCTLA4-Ig
mCTLA4-Ig
Mean Relative fluorescence Intensity
CTLA4-Ig concentration (µg/ml)
0
2
4
6
8
10
0.001
0.01
0.1
1
10
100
1000

FIG. 18


Cell Number
control antibody
Anti-HLA-DR antibody
0.1
1
10
100
1000
FL1 LOG

FIG. 19


Mean CPM (x10⁻³)
10
7.5
5
2.5
0
T cells alone
Control (DR1–)
B7 + (DR1+)
B7 – (DR1+)
Stimulators

FIG. 20


Mean CPM (x10⁻³)
80
60
40
20
0
Control (DR1–)
B7 + (DR1+)
B7 – (DR1+)
T cells alone
75
50
25
0
Control (DR1–)
B7 + (DR1+)
B7 – (DR1+)
T cells alone

FIG. 21


Mean CPM (x10⁻³)
150
100
50
0
T cell alone
+PBMC + IPEC
+ IPEC
+ (B7+DR1+) + IPEC
Stimulator population

US
#4

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to PCT International Applications)	ATTORNEY DOCKET NUMBER 2292/0H795

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed for and which a patent is sought on the invention entitled:

IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2(B7/CD28 INTERACTION)

the specification of which (check only one item below):

[X] is attached hereto.

[] was filed as United States application

Serial No. _____

on _____

and was amended

on _____ (if applicable).

[X] was filed as PCT international application

Number PCT/GB99/01350

on 30 April 1999

and was amended under PCT Article 19

on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
Great Britain	9809280.2	30 April 1998	[X] YES []NO
			[] YES [] NO
			[] YES [] NO
			[] YES [] NO
			[] YES [] NO

JS

Combined Declaration for Patent Application and Power of Attorney (Continued) (Includes Reference to PCT International Applications)	ATTY'S DOCKET NUMBER 2292/0H795

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

U.S APPLICATIONS		STATUS (Check one)		
U.S APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S SERIAL NUMBER ASSIGNED (if any)			

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Morris Nelson #15,108, Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen 19,407, Henry Sternberg #22,408, Peter C. Schechter #31,662, Robert Schaffer #31,194, Robert C. Sullivan, Jr. #30,499, and Joseph R. Robinson #33,448

Send Correspondence to:	**Direct Telephone Calls to:** **(name and telephone number)**
DARBY & DARBY P.C. 805 Third Avenue New York, New York 10022-7513	(212) 527-7700 Paul F. Fehlner

2	FULL NAME OF INVENTOR	FAMILY NAME LECHLER 1-00	FIRST GIVEN NAME Robert	SECOND GIVEN NAME Ian
0	RESIDENCE & CITIZENSHIP	CITY London W12 0NN GBX	STATE OR FOREIGN COUNTRY United Kingdom	COUNTRY OF CITIZENSHIP United Kingdom
1	POST OFFICE ADDRESS	POST OFFICE ADDRESS Hammersmith Hospital	CITY London W12 0NN	STATE & ZIP CODE/COUNTRY United Kingdom
2	FULL NAME OF INVENTOR	FAMILY NAME DORLING 2-00	FIRST GIVEN NAME Anthony	SECOND GIVEN NAME
0	RESIDENCE & CITIZENSHIP	CITY London W12 0NN GBX	STATE OR FOREIGN COUNTRY United Kingdom	COUNTRY OF CITIZENSHIP United Kingdom
2	POST OFFICE ADDRESS	POST OFFICE ADDRESS Hammersmith Hospital	CITY London W12 0NN	STATE & ZIP CODE/COUNTRY United Kingdom
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
3	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
Robert Lechler	A. Darling	
DATE 13.11.00	DATE 13/11/00	DATE